Davos is sponsoring γ-tocotrienol for the treatment of prostate cancer, a pre-clinical research by Australian Prostate Cancer Research Institute
Prostate cancer is the most common type of cancer in developed countries. The research team have discovered a particular form of T3, called gamma-tocotrienol (γ-T3), can successfully kill off the prostate cancer CSCs.